ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
IMA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ImageneBio IncNASDAQ: IMA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.12M rose 8.4% year over year, ahead of the -9.1% change in trailing-twelve-month selling, general & admin. Over 3 fiscal years it compounded at -2.3% a year.
Context
- Selling, general & admin amounted to 2590.8% of revenue in FY2025, up 2351.0 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $2.25M (-89.2%) for the fiscal year ending Dec 2026, a slowdown from the +147.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.12M+1753.5% QoQ
- Last fiscal yearDec 2025
- $20.73M+147.0% YoY
- LTMMar 2026
- $21.2M-9.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 20.73M USD
- Year-over-year change
- +147.0%
- 4-year CAGR
- +3.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.73M | +147.0% |
| FY2024 | 2024-12-31 | 8.39M | -66.3% |
| FY2023 | 2023-12-31 | 24.93M | +12.3% |
| FY2022 | 2022-12-31 | 22.2M | +23.2% |
| FY2021 | 2021-12-31 | 18.02M | — |
Selling, General & Admin vs competitors
How IMA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.1% is the 6th highest of 9, against a peer median of -6.6%.
- Over three fiscal years its annual growth of -2.3% compares with a peer median of -0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.33M USD | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $24.75M USD | -6.4% | -9.4% | 347.5% | |
IMAImageneBio Inc | LTM Mar 2026 | $21.2M USD | -9.1% | -2.3% | — |
| FY2025 | $20.34M USD | +5.8% | -0.8% | 31781.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $20.27M USD | +8.2% | -0.8% | — |
| LTM Mar 2026 | $17.37M USD | -6.9% | -4.3% | 1736.5% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $15.32M USD | -41.8% | +90.0% | — |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| LTM Mar 2026 | $8.11M USD | +9.0% | +0.2% | — | |
| Peer median (excluding IMA) | — | -6.6% | -0.8% | 1736.5% | |
Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.99M | 15.62M | 9.16M | 3.5M | 800K |
| Cost of Revenue | 47.11M | 64.32M | 1.02M | 1.53M | 1.03M |
| Gross Profit | (16.12M) | (48.7M) | 8.14M | 3.5M | (233K) |
| Gross Margin | -52.0% | -311.8% | 88.9% | 100.0% | -29.1% |
| Research & Development | 47.11M | 64.32M | 59.65M | 32.11M | 28.53M |
| Selling, General & Admin | 18.02M | 22.2M | 24.93M | 8.39M | 20.73M |
| Operating Expenses | 18.02M | 22.2M | 83.56M | 40.5M | 48.22M |
| Depreciation & Amortization | 544K | 751K | 1.02M | 1.53M | 1.03M |
| EBITDA | (33.57M) | (68.01M) | (67.31M) | (35.03M) | (44.67M) |
| EBITDA Margin | -108.3% | -435.5% | -734.8% | -1000.8% | -5583.3% |
| Operating Income | (34.14M) | (70.9M) | (75.42M) | (37M) | (48.45M) |
| Operating Margin | -110.2% | -454.0% | -823.3% | -1057.1% | -6056.4% |
| Interest Income | 23K | 2.15M | 7.11M | 7.37M | 2.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 23K | 2.14M | 7.09M | 445K | 2.75M |
| Income Before Tax | (34.12M) | (68.77M) | (68.33M) | (36.56M) | (45.7M) |
| Pre-Tax Margin | -110.1% | -440.3% | -745.9% | -1044.4% | -5712.4% |
| Income Tax Expense | 0 | 0 | (162K) | 13K | (350K) |
| Net Income | (34.12M) | (68.77M) | (68.17M) | (36.57M) | (45.35M) |
| Net Margin | -110.1% | -440.3% | -744.2% | -1044.8% | -5668.6% |
| EPS (Basic) | (0.95) | (1.90) | (1.63) | (1.02) | (10.76) |
| EPS (Diluted) | (0.95) | (1.90) | (1.63) | (1.02) | (10.76) |
| Weighted Avg Shares | 35.98M | 36.19M | 41.74M | 48.26M | 4.87M |
| Weighted Avg Shares (Diluted) | 35.98M | 36.19M | 41.74M | 48.26M | 4.87M |
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.